- Ceribell, Inc., a Mountain View, CA-based developer of a non-invasive brain monitor, completed a $53m Series C financing
- The round co-led by Longitude Capital and The Rise Fund with participation from new investors RA Capital Management, Redmile Group and Red Tree Venture Capital, with existing shareholders
- The company will use the funds to further expand its commercial presence in emergency departments and intensive care units globally
- The Ceribell® technology platform designed to address the need for faster diagnosis in patients with suspicion of seizure
- Ceribell also provides an FDA cleared, point of care brain monitor that uses real-time cloud computing and the proprietary Clarity™ machine learning algorithm
- The Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States
